{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-23-006005","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2023-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.300081+00:00","generated_at":"2026-06-09T13:59:39.998527+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Citius Pharma to spin off Citius Oncology via merger with SPAC TenX Keane","bullets":["Citius Pharma (CTXR) entered a merger agreement for its subsidiary Citius Oncology to combine with TenX Keane Acquisition.","Upon close, TenX will domesticate to Delaware and change name to 'Citius Oncology, Inc.'; expected close first half 2024.","SpinCo shares convert to New Citius Oncology shares using Base Exchange Ratio of 67.5M / outstanding SpinCo shares.","Termination rights include FDA CRL for Lymphir; $5M termination fee payable by Citius Pharma under certain conditions.","Sponsor 10XYZ Holdings supports transaction; post-close registration rights and shared services agreements planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-23-006005","json":"https://secwatch.observer/filing/0001013762-23-006005.json","markdown":"https://secwatch.observer/filing/0001013762-23-006005.md","text":"https://secwatch.observer/filing/0001013762-23-006005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000101376223006005/0001013762-23-006005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000101376223006005/ea186984-8k425_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T13:59:39.998527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92941e70d0c0c7958a78a9338e170fd1fcc58b08","claim":"Citius Pharmaceuticals, Inc. entered into Merger Agreement with TenX Keane Acquisition (effective 2023-10-23).","evidence_excerpt":"On October 23, 2023, Citius Pharmaceuticals, Inc. (“Citius Pharma”) and Citius Oncology, Inc. (“SpinCo”), a wholly owned subsidiary of Citius Pharma, entered into an agreement and plan of merger and reorganization (the “Merger Agreement”) with TenX Keane Acquisition, a Cayman Islands exempted company (“TenX”), and TenX Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of TenX (“Merger Sub”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000101376223006005/0001013762-23-006005-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"TenX Keane Acquisition"},{"label":"Effective","value":"2023-10-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}